Deutsch English Français

Contact

EP1053023

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1053023

EP1053023 - SYSTEMIC DELIVERY OF SERUM STABLE PLASMID LIPID PARTICLES FOR CANCER THERAPY [Right-click to bookmark this link]
Status	Patent maintained as amended Status updated on 25.02.2011 Database last updated on 09.09.2024
Most recent event Tooltip	25.02.2011	Patent maintained (B2 publication)	published on 30.03.2011 [2011/13]
Applicant(s)	For all designated states Protiva Biotherapeutics Inc. 100-8900 Glenlyon Parkway Burnaby, British Columbia V5J 5J8 / CA
	[2011/01]
Former [2007/27]	For all designated states Protiva Biotherapeutics Inc. 100- 3480 Gilmore Way Burnaby BC V5G 4Y1 / CA
Former [2007/18]	For all designated states Provita Biotherapeutics Inc. 100- 3480 Gilmore Way Burnaby BC V5G 4Y1 / CA
Former [2000/47]	For all designated states Inex Pharmaceuticals Corp. 100-8900 Glenlyon Parkway, Glenlyon Business Park Burnaby, British Columbia V5J 5J8 / CA
Inventor(s)	01 / MACLACHLAN, Ian Apt. 302, 1812 W. 7th Avenue Vancouver, British Columbia V6J 1S8 / CA
	02 / GRAHAM, Roger 2638 W. 7th Avenue Vancouver, British Columbia V6K 1Z1 / CA
	[2000/47]
Representative(s)	Campbell, Patrick John Henry J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
	[N/P]
Former [2003/23]	Campbell, Patrick John Henry J.A. Kemp & Co., 14 South Square, Gray's Inn London WC1R 5JJ / GB
Former [2000/47]	West, Alan Harry R.G.C. Jenkins & Co. 26 Caxton Street London SW1H 0RJ / GB
Application number, filing date	99903557.9	03.02.1999
	[2000/47]
	WO1999CA00090
Priority number, date	US19980073598P	03.02.1998 Original published format: US 73598 P
	US19980086917P	27.05.1998 Original published format: US 86917 P
	US19980101429P	22.09.1998 Original published format: US 101429 P
	US19980112384P	14.12.1998 Original published format: US 112384 P
	US19990243102	02.02.1999 Original published format: US 243102
	[2000/47]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO9939741
	Date:	12.08.1999
	Language:	EN
	[1999/32]
	Type:	A2 Application without search report
	No.:	EP1053023
	Date:	22.11.2000
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 12.08.1999 takes the place of the publication of the European patent application.
	[2000/47]
	Type:	B1 Patent specification
	No.:	EP1053023
	Date:	04.07.2007
	Language:	EN
	[2007/27]
	Type:	B2 New European patent specification
	No.:	EP1053023
	Date:	30.03.2011
	Language:	EN
	[2011/13]
Search report(s)	International search report - published on:	EP	30.09.1999
Classification	IPC:	A61K48/00	[2000/47]
	CPC:	A61K48/00 (EP); A61K38/208 (EP); A61K38/45 (EP); A61K38/51 (EP); A61P35/00 (EP); C12N15/88 (EP)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2000/47]
Title	German:	SYSTEMISCHE VERABREICHUNG VON SERUM-STABILEN PLASMID-LIPID PARTIKELN ZUR KREBSTHERAPIE	[2000/47]
	English:	SYSTEMIC DELIVERY OF SERUM STABLE PLASMID LIPID PARTICLES FOR CANCER THERAPY	[2000/47]
	French:	ADMINISTRATION SYSTEMIQUE DE PARTICULES LIPIDIQUES DU PLASMIDE STABLES DANS LE SERUM EN CANCEROTHERAPIE	[2000/47]
Entry into regional phase	04.09.2000	National basic fee paid
	04.09.2000	Designation fee(s) paid
	04.09.2000	Examination fee paid
Examination procedure	03.09.1999	Request for preliminary examination filed International Preliminary Examining Authority: EP
	04.09.2000	Examination requested [2000/47]
	17.12.2002	Despatch of a communication from the examining division (Time limit: M08)
	01.07.2003	Reply to a communication from the examining division
	03.05.2004	Despatch of a communication from the examining division (Time limit: M04)
	10.09.2004	Reply to a communication from the examining division
	10.10.2006	Minutes of oral proceedings despatched
	25.10.2006	Date of oral proceedings
	06.11.2006	Communication of intention to grant the patent
	25.04.2007	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
	30.04.2007	Fee for grant paid
	30.04.2007	Fee for publishing/printing paid
Opposition(s)	Opponent(s)	01 04.04.2008 ADMISSIBLE Lammert, Roland, Dr. Hermanstr. 25d 86150 Augsburg / DE Opponent's representative Wachenfeld, Joachim, et al, et al Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 4 81675 München / DE
		[N/P]
	Former [2008/20]
	Opponent(s)	01 04.04.2008 ADMISSIBLE Lammert, Roland, Dr. Hermanstr. 25d 86150 Augsburg / DE Opponent's representative Wachenfeld, Joachim, et al, et al Vossius & Partners, Siebertstrasse 4 81675 München / DE
	09.05.2008	Invitation to proprietor to file observations on the notice of opposition
	19.11.2008	Reply of patent proprietor to notice(s) of opposition
	29.04.2010	Legal effect of interlocutory decision in opposition
	29.04.2010	Date of oral proceedings
	13.07.2010	Despatch of interlocutory decision in opposition
	13.07.2010	Despatch of minutes of oral proceedings
	18.11.2010	Despatch of communication that the patent will be maintained as amended
	14.02.2011	Fee for printing new specification paid
Request for further processing for:	30.04.2007	Request for further processing filed
	30.04.2007	Full payment received (date of receipt of payment) Request granted
	21.05.2007	Decision despatched
Fees paid	Renewal fee
	22.01.2001	Renewal fee patent year 03
	25.02.2002	Renewal fee patent year 04
	25.02.2003	Renewal fee patent year 05
	23.02.2004	Renewal fee patent year 06
	22.02.2005	Renewal fee patent year 07
	27.02.2006	Renewal fee patent year 08
	27.02.2007	Renewal fee patent year 09
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AT	04.07.2007
	BE	04.07.2007
	CY	04.07.2007
	DK	04.07.2007
	FI	04.07.2007
	SE	04.10.2007
	GR	05.10.2007
	ES	15.10.2007
	PT	04.12.2007
	LU	03.02.2008
	MC	28.02.2008
	[2010/28]
Former [2010/06]	AT	04.07.2007
	BE	04.07.2007
	CY	04.07.2007
	DK	04.07.2007
	FI	04.07.2007
	SE	04.10.2007
	GR	05.10.2007
	ES	15.10.2007
	PT	04.12.2007
	MC	28.02.2008
Former [2008/46]	AT	04.07.2007
	BE	04.07.2007
	DK	04.07.2007
	FI	04.07.2007
	SE	04.10.2007
	GR	05.10.2007
	ES	15.10.2007
	PT	04.12.2007
	MC	28.02.2008
Former [2008/28]	AT	04.07.2007
	BE	04.07.2007
	DK	04.07.2007
	FI	04.07.2007
	SE	04.10.2007
	GR	05.10.2007
	ES	15.10.2007
	PT	04.12.2007
Former [2008/23]	AT	04.07.2007
	BE	04.07.2007
	DK	04.07.2007
	FI	04.07.2007
	GR	05.10.2007
	ES	15.10.2007
	PT	04.12.2007
Former [2008/21]	AT	04.07.2007
	BE	04.07.2007
	FI	04.07.2007
	GR	05.10.2007
	ES	15.10.2007
	PT	04.12.2007
Former [2008/17]	AT	04.07.2007
	FI	04.07.2007
	ES	15.10.2007
	PT	04.12.2007
Cited in	International search	[XY]WO9106309 (UNIV VANDERBILT [US]) [X] 1-29,31-34 * page 4, line 3 - page 11, line 28 * [Y] 30;
		[A]WO9505853 (UNIV CALIFORNIA [US], et al) [A] * page 14, line 14 - page 18, line 8 *;
		[DXY]WO9640964 (INEX PHARMACEUTICALS CORP [CA], et al) [DX] 1-29,31-34 * page 3, line 22 - page 5, line 7 * * page 37, line 18 - page 40, line 5 * [Y] 30;
		[Y]WO9639831 (UNIV CALIFORNIA [US]) [Y] 30 * page 3, line 6 - page 4, line 16 * * page 8, line 29 - page 10, line 4 * * page 26, line 14 - page 29, line 17 *;
		[A] - NABEL, GARY J. (1) ET AL, "Direct gene transfer with DNA - liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1993) VOL. 90, NO. 23, PP. 11307-11311. ISSN: 0027-8424., XP002110798 [A] * page 11307 * * abstract * * page 11307, paragraph 3 - page 11308, paragraph 1 * DOI: http://dx.doi.org/10.1073/pnas.90.23.11307
		[DA] - MOOLTEN, "TUMOR CHEMOSENSITIVITY CONFERRED BY INSERTED HERPES THYMIDINE KINASE GENES: PARADIGM FOR A PROSPECTIVE CANCER CONTROL STRATEGY", CANCER RESEARCH, (1986), vol. 46, pages 5276 - 5281, XP000610741 [DA] * page 5276 * * abstract *
	by applicant	WO9106309
		WO9312240
		WO9324640
		WO9529242
		WO9603515
		WO9622277
		WO9640964
		US5589466
		WO9707118
		WO9715666
		WO9719180
		WO9719183
		US5641662
		US5676954
		US5705385
		- STRIBLING ET AL., PNAS, (1992), vol. 89, pages 11277 - 11281
		- MCLACHLAN ET AL., GENE THERAPY, (1995), vol. 2, pages 614 - 622
		- CANONICO ET AL., AM. J. RESPIR. CELL MOL. BIOL., (1994), vol. 10, pages 24 - 29
		- CANONICO ET AL., THE AMERICAN PHYSIOLOGICAL SOCIETY, (1994), pages 415 - 419
		- ALTON ET AL., NATURE GENETICS, (1993), vol. 5, pages 135 - 142
		- CAPELEN ET AL., NATURE MEDICINE, (1995), vol. 1, no. 1, page 39
		- MCLACHLAN ET AL., GENE THER., (1996), vol. 3, no. 12, pages 1113 - 23
		- MONNARD ET AL., "Entrapment of nucleic acids in liposomes", BIOCHIM. BIOPHYS. ACTA, (1997), vol. 1329, pages 39 - 50
		US19950399692
		US19950485458
		US19950484282
		US19960588542
		US19960607614
		US19960660025
		US19970856374
		US19970063473
		US19980082665

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p